

AUSTEDO XR - (6 mg, 12 mg, and 24 mg ; Extended-release Tablets)

Generic Name	DEUTETRABENAZINE	Innovator	Teva
Dosage	6 mg, 12 mg, and 24 mg ; Extended-release Tablets	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	AUSTEDO XR is vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of: • Chorea associated with Huntington's disease • Tardive dyskinesia		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.